CUE Stock Forecast: Cue Biopharma, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Cue Biopharma, Inc. is $66. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 20 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Cue Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (5): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CUE stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CUE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Nov 2026 | B. Riley Securities | Reiterates | Buy | $83 → $25 |
| 18 Sept 2026 | B. Riley Securities | Initiates | Buy | $83 |
| 25 Aug 2025 | LUCID CAPITAL MARKETS | Initiates | Buy | $4.00 |
| 2 Apr 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 20 Aug 2024 | Stifel | Maintains | Buy | — |
| 26 July 2024 | JMP Securities | Maintains | Market Outperform | — |
| 26 July 2024 | Piper Sandler | Maintains | Overweight | — |
| 9 Apr 2024 | Oppenheimer | Maintains | Outperform | — |
| 9 Apr 2024 | Stifel | Maintains | Buy | — |
| 3 Apr 2024 | Piper Sandler | Reiterates | Overweight | — |
| 13 Mar 2024 | Jefferies | Initiates | Buy | — |
| 6 Nov 2023 | Piper Sandler | Maintains | Overweight | — |
| 26 June 2023 | Oppenheimer | Assumes | Outperform | $10 |
| 15 June 2023 | Stifel | Reiterates | Buy | — |
| 15 May 2023 | JMP Securities | Reiterates | Outperform | — |
| 22 Mar 2023 | Oppenheimer | Reiterates | Outperform | — |
| 22 Mar 2023 | Stifel | Maintains | Buy | — |
| 21 Nov 2022 | Piper Sandler | Initiates | Overweight | — |
| 24 Aug 2022 | Oppenheimer | Maintains | Outperform | — |
| 21 Mar 2022 | Oppenheimer | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CUE.
This page is one stock. Monday covers all of them.
CUE appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CUE vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Cue Biopharma, Inc. returned −74.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CUE analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.1×
- Price / book
- 0.9×
- EV / EBITDA
- —
Cheaper than 64% of US stocks
Cheaper than 74% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −800.4%
- Return on assets
- −174.2%
- Dividend yield
- —
Higher than 2% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cue Biopharma, Inc. has a market value of $37.6M.
Revenue in the twelve months to 30 June 2026: $37.7M. The latest quarter grew 166.7% year on year.
Net income over the same four quarters: −$164.1M, a −435.8% net margin.
Diluted earnings per share, trailing twelve months: −$27.02.
Free cash flow in the twelve months to 30 June 2026: −$50.2M.
Cue Biopharma, Inc. employs 29 people — $1.3M of revenue per employee.
Data provided by Twelve Data
CUE and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CUE’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Cue Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CUE
What is the CUE stock price forecast for 2026-2027?
The median 12-month analyst price target for Cue Biopharma, Inc. is $66, with estimates ranging from $25 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CUE stock a buy right now?
Of the 3 analysts covering Cue Biopharma, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cue Biopharma, Inc. 20 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CUE?
As at 21 Nov 2026, Cue Biopharma, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).
Will CUE stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts is $66, and Ticker Nerd's factor model ranks Cue Biopharma, Inc. 20 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CUE stock forecast for 2030?
No analyst covering Cue Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CUE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $115 over the next 12 months.
How has CUE stock performed over the past year?
Cue Biopharma, Inc. returned -74.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Cue Biopharma, Inc. do?
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision immunotherapies for allergic and autoimmune diseases. Its current portfolio centers on therapeutic biologics designed to selectively modulate disease-specific T cells and restore immune balance without broad immune suppression.
About Cue Biopharma, Inc.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision immunotherapies for allergic and autoimmune diseases. Its current portfolio centers on therapeutic biologics designed to selectively modulate disease-specific T cells and restore immune balance without broad immune suppression. The company’s lead asset, CUE-221, is an anti-IgE antibody being advanced for allergic diseases, while CUE-401 is a bifunctional IL-2 and TGF-β program designed to support Treg-mediated tolerance in autoimmune conditions. Cue Biopharma’s Immuno-STAT platform underpins its product development approach, enabling targeted immune modulation across immunological disorders. Based in Boston, Massachusetts, Cue Biopharma participates in the biotechnology sector through a pipeline aimed at addressing unmet medical needs in allergy, inflammation, and autoimmunity.
CEO Dr. Shao-Lee Lin M.D., Ph.D. · 29 employees · United States · https://www.cuebiopharma.com